DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
05/11/2023* 08:30 EST Earnings Call Q1 2023 -- -- --
05/10/2023* -- Results Q1 2023 -- 0.31 --
03/16/2023 08:30 EST Earnings Call Q4 2022 -- -- --
03/15/2023 -- Results Q4 2022 0.22 0.20 11.86%
11/10/2022 08:30 EST Earnings Call Q3 2022 -- -- --
11/09/2022 -- Results Q3 2022 0.24 0.19 23.77%
08/10/2022 08:30 EST Earnings Call Q2 2022 -- -- --
08/09/2022 -- Results Q2 2022 0.20 0.17 21.21%
*Estimated Date/Time

Earnings

Next Report Date 05/10/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 03/15/2023
Beat/Miss Upgrade
Return Since 16.60%
Last FQE 12/31/2022
Next FQE 03/31/2023

Profile

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
URL https://www.catalystpharma.com
Investor Relations URL https://ir.catalystpharma.com/
HQ State/Province Florida
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release May. 10, 2023 (est.)
Last Earnings Release Mar. 15, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Annual Total Returns Versus Peers

Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
-57.14%
272.4%
-50.90%
95.31%
-10.93%
102.7%
174.7%
-10.11%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
5.35%
-36.56%
-37.30%
-25.55%
67.36%
-51.25%
-27.69%
175.2%
-15.72%
-21.63%
-53.52%
-72.88%
319.3%
-13.79%
-83.00%
159.1%
64.21%
--
--
-7.50%
-14.58%
29.49%
-66.43%
191.8%
-40.11%
-48.35%
-63.62%
-62.34%
16.94%
118.7%
-43.25%
193.1%
6.46%
As of March 29, 2023.

Profile

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
URL https://www.catalystpharma.com
Investor Relations URL https://ir.catalystpharma.com/
HQ State/Province Florida
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release May. 10, 2023 (est.)
Last Earnings Release Mar. 15, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
TGFRX 1.360M USD 8.79%
PBE 7.558M USD 3.06%
YOVAX 763000.0 USD 2.11%
PTH 3.522M USD 1.95%
PSCH 4.678M USD 1.63%
BPLEX 921059.0 USD 1.30%
XBI 71.56M USD 1.11%
HIL269 4.862M USD 1.09%
IMPAX 829541.0 USD 1.03%
DWAS 4.597M USD 0.92%
QSMNX 1.053M USD 0.91%
LABU 7.444M USD 0.85%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter CPRX Tweets